Jci_page_head_homepage_01 Jci_page_head_homepage_02
Craig Brooks, Qingqing Wei, Sung-Gyu Cho, Zheng Dong
Published in Volume 119, Issue 5
J Clin Invest. 2009; 119(5):1275–1285 doi:10.1172/JCI37829
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Inhibition of mitochondrial fragmentation and membrane permeabilization by Bcl2 and not by VAD.

Wild-type and Bcl2-overexpressing RPTCs were transfected with MitoRed to label mitochondria. The cells were then treated with azide (10 mM, 3 hours) or cisplatin (20 μM, 16 hours) in the absence or presence of 100 μM VAD. Mitochondrial morphology in individual cells was evaluated by fluorescence microscopy to determine the percentage of cells with mitochondria fragmentation. (A) Mitochondrial fragmentation during azide-induced ATP depletion. (B) Mitochondrial fragmentation during cisplatin incubation. (C) Cytochrome c (Cyt. c) release during azide treatment. Cells were fractionated to collect cytosolic fraction for immunoblot analysis of cytochrome c. Data in A and B are presented as mean ± SD; n ≥ 3. *P < 0.05, significantly different from untreated control; #P < 0.05, significantly different from azide- or cisplatin-treated RPTCs. Results show that Bcl2 (but not caspase inhibitors) can suppress mitochondrial fragmentation and outer membrane permeabilization. Ctrl, control.